Interaction between regulatory T cells and mast cells via IL-9 and TGF-β production

YI-BIN ZHAO, SHAO-HUI YANG, JIE SHEN, KE DENG, QI LI, YU WANG, WEI CUI and HUA YE

Department of Gastroenterology, Ningbo Medical Treatment Center, Lihuili Hospital, Ningbo, Zhejiang 315040, P.R. China

Received October 19, 2019; Accepted August 24, 2020

DOI: 10.3892/ol.2020.12224

Abstract. Research on the immunosuppression of cancer cells has attracted much attention in recent years. The present study sought to provide a new strategy for tumor immunotherapy targeting mast cells by studying the mechanisms underlying mast cell function in cancer immunosuppression. Between January 2015 and December 2017, the tumor tissues of 40 patients with gastric cancer (GC) were collected and grouped in Lihuili Hospital of Ningbo City, China. Pathological sections were prepared and an immunofluorescence assay was performed to analyze the expression of forkhead Box Protein P3 (FOXP3), tryptase, TGFβ1, TGF-βR, IL-9, IL-9R and Oxford 40 ligand (OX40L). Then, the correlations between FOXP3 and tryptase, TGFβ1 and tryptase expression, and the expression of OX40L in patients with GC with different stages were analyzed. The results revealed that high levels of mast cells were present in patients GC, and tryptase and FOXP3 expressions were positively correlated. Mast cells regulate T regulatory (reg) cells in the gastric tumor microenvironment by secreting TGFβ1. Tregs, in turn, promote the survival of mast cells in the tumor microenvironment by producing IL-9. Furthermore, OX40L expression in mast cells was significantly associated with Tumor‑Node‑Metastasis staging of GC. Overall, the present study reported a positive feedback system by which MCs regulate cancer immunosuppression, in the hope that improving our understanding of these functions may provide novel insights and possibly a new strategy for tumor immunotherapy targeting mast cells.

Introduction

Gastric cancer (GC) is one of the most common digestive malignancies throughout the world (1). It remains an important cancer worldwide and was responsible for over 1,000,000 new cases in 2018 and an estimated 783,000 mortalities, making it the fifth most frequently diagnosed cancer and the third leading cause of cancer-associated mortality (1). Despite the declining morbidity and mortality rates among patients with GC in the majority of developed countries, the disease remains largely incurable and is still the second leading cause of cancer-associated death worldwide (2,3). Meanwhile, the treatment options available to patients with GC remain limited. Due to the lack of obvious early symptoms of GC and insufficient popularization of routine gastroscopy test, about 80% of GC cases have been diagnosed at an advanced stage. For GC treatment, besides surgical treatment, radiotherapy and chemotherapy are still frequently used adjuvant treatment methods (4). Immunotherapy has received great interest in recent years; however, it has not become a major treatment option for GC (5). Tumor immunotherapy is gaining significant popularity in the field of cancer treatment, benefiting from the in-depth study of cancer immunosuppression in recent years (5). However, few tumor immunosuppression studies have focused on the role of mast cells (MCs) in this process. Therefore, the present study aimed to investigate the mechanisms by which MCs regulate cancer immunosuppression, in the hope that improving our understanding of these functions may provide novel insights and possibly a new strategy for tumor immunotherapy targeting MCs.

MCs are a group of long-lived heterogeneous cells originating from bone marrow (6). Their effects on tumor development are numerous and complex as MCs were originally identified by their roles in angiogenesis (7) and inflammation. For example, accumulation of MCs has been found to accelerate inflammation and aggravate immunosuppression in the tumor microenvironment via the stem cell factor (SCF)/c-kit signaling pathway (8). However, previous work has also revealed a role for MCs in regulating the adaptive immune response (6).

Tumor-induced immune suppression hinders the cytotoxic responses of T lymphocytes, as well as natural killer cells, and promotes tumor progression (9). There are various immunosuppressive mechanisms in which tumors and regulatory T cells (Tregs) play a vital role (9,10). Treg cells, which are characterized by expression of the transcription factor forkhead box protein (Foxp)3 in the nucleus, are a functionally distinct subset of T lymphocytes with immunosuppressive capacities necessary for maintaining immune tolerance (11,12). Through
the interaction between MCs and Tregs influence the intensity of tumor-induced inflammation, and can result in either the promotion or inhibition of tumor growth (6). An increase in MCs has been observed in numerous experimental animal tumor models, as well as human tumor specimens (13,14). Our previous study provided evidence of a clear correlation between the number of MCs and expression of Foxp3 in human GC (15), but the mechanism underlying this correlation remains unclear. Therefore, the present study aimed to resolve these mechanisms in GC.

OX40, the receptor of OX40L, could be expressed by effector and memory CD4+ T cells (16). Studies have shown that inhibition of OX40/OX40L signaling pathway can regulate inflammation and immune response and thereby promote GC patient recovery (17), suggesting OX40L may be related to the progression of GC, and can act as a marker to determine the malignancy and prognosis of GC. However, no research on this has been reported so far. Therefore, the results presented in this study may help to elucidate a new strategy for GC immunotherapy targeting MCs.

Materials and methods

Patients and specimens. Samples were collected from 40 patients with GC at the Ningbo Medical Center of Lihuili Hospital (Ningbo, China) following approval from the Ethics Committee of Lihuili Hospital (approval no. KY2020PI020). Written consent was obtained from the patients prior to the collection of samples. The inclusion and exclusion criteria were as follows: i) Diagnosis of GC confirmed by pathology; ii) without anticancer treatment before surgery; iii) underwent curative resection for GC between January 2015 and December 2017 (patients in stage IV underwent resection only); iv) with complete clinicopathological and follow-up data. Postoperatively, all the specimens were stored using paraffin. The specimens were fixed in 4% paraformaldehyde at 25°C for 4 h, and then transferred to 70% ethanol. The individual lobes of tumor biopsy material were placed in processing cassettes, dehydrated through a serial alcohol gradient, embedded in paraffin wax blocks, and then subjected to paraffin section with a thickness of 5 µm. Clinical stages were classified according to the 7th Tumor-Node-Metastasis (TNM) staging system (18). The clinical characteristics of all patients are summarized in Table I.

Immunofluorescence. Primary rabbit anti-Mast Cell Tryptase (MCT) (1:500; cat. no. bs-2725R; BIOSS) and mouse anti-FoxP3 (1:500; cat. no. sc-166212; Santa Cruz Biotechnology, Inc.) antibodies were used to detect MCT cells and FoxP3 expression, respectively. Other primary antibodies including rat anti-OX40 (1:500; cat. no. sc-71768; Santa Cruz Biotechnology, Inc.), mouse anti-IL-9R (1:500; cat. no. sc-515622; Santa Cruz Biotechnology, Inc.), rabbit anti-IL-9 (1:500; cat. no. bs-10435R; BIOSS) and rabbit anti-TGFβ1 (1:500; cat. no. bs-0086R; BIOSS) antibodies were also used. Before immunofluorescence analysis, the sections were blocked with donkey serum albumin (1:50; cat. no. BMS0140; Abbkine Scientific Co., Ltd.) in PBS for 1 h at room temperature and then incubated at 4°C with the aforementioned primary antibodies. Then the sections were incubated with secondary goat anti-rat IgG antibody (1:500; cat. no. bs-0293G), goat anti-rabbit IgG antibody (1:500; cat. no. bs-0295G) or goat anti-Mouse IgG antibody (1:500; bs-0296G) (all BIOSS) at 37°C for 1 h. Slides were then mounted with Vectashield containing DAPI (Vector Laboratories, Inc.; Maravai LifeSciences) and visualized and images captured using a fluorescence microscope (Olympus Corporation; magnification, x200) coupled to a CCD camera (Nikon Corporation). Negative controls, in which PBS was used in place of primary antibodies, were included for each marker. The mean intensity of fluorescence was analyzed using ImageJ (version 1.45r; National Institutes of Health).

Table I. Clinical characteristics and the stages of the patients with gastric cancer.

| Characteristics | Value |
|-----------------|-------|
| Sex, male/female | 23/17 (57.5/42.5) |
| Age, years | 30-75 |
| TNM stage |  |
| I | 10 (20) |
| II | 10 (20) |
| III | 10 (20) |
| IV | 10 (20) |

*Presented as n (%). †Presented as range. TNM, tumor-node-metastasis.

Statistical analysis. All statistical analyses were performed using SPSS version 14.0 software (SPSS Inc.). The results are expressed as mean ± standard error of the mean of three independent experiments. The means of the tumor and non-tumor groups were compared using a paired Student's t-test. Multiple comparisons were performed using a one-way analysis of variance followed by Tukey's post hoc test, which was used to analyze clinical stages in relation to mean levels of OX40L. P<0.05 was considered to indicate a statistically significant difference. Relationships between tryptase and Foxp3, and tryptase and TGFβ1 in GC tissue or from The Cancer Genome Atlas database (https://tcga-data.nci.nih.gov/tcga) were analyzed with the Spearman's rank correlation coefficient.

Results

The role of MCs in regulating microenvironment immunity of GC. MCs play an important role in the tumor microenvironment of GC (15), therefore, to clarify the role of MCs in GC, an immunofluorescence assay to detect the expression of MCs in 40 human paired GC and non-tumor tissue samples. As shown in Fig. 1A and B, tryptase was upregulated in GC specimens compared with the surrounding non-tumor tissues. In total, 20 of the 40 samples were used to detect Foxp3 expression in GC tissues. The results showed that MCs displayed high levels of Foxp3 in GC samples and tryptase and Foxp3 expressions were positively correlated in human GC (P<0.05; Fig. 1C), which suggests that the infiltration of MCs in GC may increase the number of Tregs and MCs may play an important role in regulating tumor immunity.
MCs regulate Treg cells in the GC tumor microenvironment by secreting TGFβ1. It has been previously reported that GC cells induce the increased human CD4+ Foxp3+ Tregs via the production of TGFβ1 (19), but whether mast cells can secrete TGFβ1 in GC is unclear. Using TCGA database, it was demonstrated that TGFβ1 expression has a positive correlation with MCs in the GC group (P<0.001; Fig. 2A). In addition, immunofluorescence was used to analyze the localization of MCs and TGFβ1 in GC tissues (Fig. 2B), and the results were examined using correlation analysis. As presented in Fig. 2C, the TGFβ1 expression exhibited a positive correlation with MCs in GC tissues (P<0.05). Furthermore, the expression of TGFβ1R in MCs was also examined. The results indicated that TGFβ1R is expressed in Treg cells (Fig. 2D). In summary, these data suggested that the cytokine TGFβ1 may be a molecule involved in crosstalk between MC and Treg cells.

Tregs regulate MCs in the tumor microenvironment by producing IL-9. Considering that IL-3, IL-4 and IL-9 affect MC proliferation but only IL-9 is able to promote the growth of MCs from bone marrow and MC progenitors (20,21), it was hypothesized that Tregs may regulate MCs through IL-9. To test this hypothesis, IL-9 and Treg cells were probed for using immunofluorescence. As expected, it was reported that Tregs secreted IL-9 (Fig. 3A). High IL-9R expression was also detected on the surface of MCs for the first time (Fig. 3B). Together, these results showed that a positive feedback regulation system may exist between MCs and Treg cells that operates through TGFβ1 and IL-9.

Expression of OX40L in MCs is an important marker for determining GC malignancy and prognosis. OX40L was also a protein of interest. Notably, in GC tissues, it was demonstrated that the majority of OX40L was expressed on
MCs, which has not been reported previously to the best of our knowledge (Fig. 4A). By analyzing clinical samples, it was found that OX40L expression in GC was significantly associated with TNM stage. As presented in Fig. 4B, there was a significant difference in OX40L levels between Stage I and Stages II-IV (P<0.001). To further confirm whether the expression of OX40L is an important marker for determining GC malignancy and prognosis, TCGA data were analyzed and there was a significant difference in OX40L levels between Stages I and II (P<0.05; Fig. 4C). This suggests that OX40L expressed by MCs may be an important marker for determining GC malignancy and prognosis.

Discussion

GC is the most common gastrointestinal tumor (1). Although the medical understanding of this disease is improving, the rates of incidence and mortality of GC are still high, especially in China. In 2018, 42.6% of new GC cases and 45% of GC-induced deaths occurred in China (22). The research on tumor immunity observed GC has led to several important discoveries (23), yet further exploration is needed, despite the progress made.

Our previous study focused on the roles of MCs in GC, reporting that the frequency of MCs is higher in tumors compared with in healthy tissues, and MC levels are correlated with TNM stage (13). Ribatti et al (14) also demonstrated that MC density is correlated with the progression gastric carcinoma and the density of MCs is positively correlated with the development of the disease from stage I to stage IV. Some studies have suggested that MCs play a protective role in human cancer (24-27); however, in GC, the overall role of MCs in promoting cancer is unclear. The tumor promoting mechanism of MCs is exceedingly complicated, and involves tissue remodeling, angiogenesis and immune regulation (14). Therefore, conducting research on MCs can be very difficult, leading the present study to focus on the immunoregulatory function of MCs. Several studies have demonstrated increased presence of intratumoral and circulating Treg cells in gastric adenocarcinomas (28-30). In gastric tumors, Treg abundance is also correlated with decreased overall survival (28,31), and, in particular, a high Foxp3 level is an independent factor associated with worse overall survival time and rate (30). In our previous study a positive correlation was identified between MCs and Tregs using flow cytometry (15). In the present study, immunofluorescence was used to further confirm this correlation and to further explore the possible mechanisms of interaction.

It is widely recognized that TGFβ plays several central roles in carcinogenesis (31-33). The TGFβ family of proteins...
regulates numerous cellular functions, including cell growth, differentiation, adhesion, migration and apoptosis. TGFβ is also able to manipulate the tumor microenvironment to promote carcinogenesis. Malignant tumor cells secrete a large amount of TGFβ protein, which not only accelerates the proliferation and migration of cancer cells, but also enables cancer cells to evade the immune system. TGFβ also induces Tregs to inhibit effector T cells, a set of cells which have the capability of recognizing and killing cancer cells like Cytotoxic T lymphocyte (34). In addition, TGFβ can act directly on effector T cells, natural killer cells and B cells, to inhibit their immunological activities (34). Yuan et al (19) found that GC cells could induce human CD4+ Foxp3+ Tregs through the production of TGFβ1. TGFβ1 is also an important product of MCs (35), but whether MCs can regulate Tregs in human GC by secreting TGFβ1 has not been previously reported. The present study demonstrated that there is a correlation between TGFβ1 and MCs in GC (Fig. 2), suggesting that MCs are also involved in TGFβ1 secretion, which can have a positive effect on Tregs.

IL-9 was also investigated, another important factor linking Tregs and MCs, which has been shown to promote MC proliferation and function (36). Previous work has shown that the number of basal MCs was normal without IL-9 (37); however the presence of IL-9, in combination with Stem cell factor, was able to promote the proliferation of MCs from bone marrow and MC progenitors (36). The primary source of IL-9 is T lymphocytes, including natural Tregs and inducible Tregs, both of which are Foxp3+ populations that are able to secrete IL-9 (38,39). However, there is conflicting evidence regarding the production of IL-9 from human Treg cells (40,41). Additionally, in human donors the co-expression of Foxp3 and IL-9 has not been reported either. There are several pieces of evidence connecting IL-9 and MCs (42). IL-9 is a key proliferation or differentiation factor and chemoattractant for MCs (43,44) and has been previously implicated as a key cytokine important for regulating the interactions between Tregs and MCs in other systems, such as inflammation (39). Furthermore, IL-9 production by Tregs recruits MCs that are essential for Treg-induced immune-suppression (45). Thus, the present study sought to analyze the functional role of IL-9 in Treg-MC interactions in GC. The current study analyzed Foxp3 and IL-9 expression in GC, and reported that these were co-expressed, indicating that Treg cells can secrete IL-9 in GC.
tissues. In addition, we discovered for the first time that IL-9R is expressed on the surface of MC. Based on these results, it is reasonable to speculate that Tregs can regulate MCs by secreting IL-9 in GC. These results suggested that a positive feedback regulation system exists between Treg cells and MCs that operates through TGFβ1 and IL-9. This feedback may have an inhibitory effect and result in cancer-mediated immunosuppression.

The present study also investigated the important molecule OX40L. It was found that patients with high expression of OX40L had a worse prognosis (Fig. 4). However, the expression of OX40L did not significantly affect the survival curve (data not shown). Further analysis showed that OX40L expression was also correlated with TNM stage (Fig. 4), and OX40L expression was higher in GC patients at late-stage (stages II-IV) compared with that in stage I patients. Previous studies have found an association between MC and TNM staging of GC (13,15), leading to the speculation that changes in OX40L expression could be caused by MCs. Previous work has shown that OX40L expression is upregulated in response to antigen presentation on multiple antigen-presenting cells (46). The type of cells that can be induced to express OX40L is broader compared with that for OX40, and studies have reported expression of OX40L on MCs (47,48), as well as vascular endothelial cells (49). In addition, MCs can also promote angiogenesis (24), suggesting that the increased expression of OX40L is likely caused by neovascularization. The results of the present study demonstrated a significant difference in OX40L levels between stage I and stages II-IV GC patients, suggesting that OX40L can be used as a potential novel GC marker for clinical evaluation of occurrence, development and metastasis of GC. Although OX40L has not been clinically used as a prognostic factor for GC and the immune-promoting effect of OX40L may not be dominant in GC, the present study does provide a new perspective on the unique role of MCs in GC.

In summary, the present results showed increased expression of both MCs and Foxp3 in GC samples compared with normal tissues. The significant correlation between MCs and Foxp3 supports the hypothesis that MCs play a role in the immune suppression seen in GC and may, at least partially, affect the prognosis. The mechanism of action between these two cell types was further investigated, revealing that there be a regulatory feedback mechanism involving TGFβ1 and IL-9. TGFβ1 has been shown to play an important role in GC (50). The current study showed that MCs are involved in the secretion of TGFβ1, and can promote Tregs through TGFβ1. Tregs can also positively regulate MCs by producing IL-9 to promote MC function. OX40L may serve as a potential prognostic indicator of GC and could provide a new perspective to study the angiogenesis in this disease. However, the present study has some limitations. First, the study only focused on tumor immunity and did not thoroughly analyze detailed clinicopathological data, hence the present data lack some important clinicopathological characteristics, such as lymph node metastasis and liver metastasis. In addition, the present study only provided preliminarily evidence to support the hypothesis that there may be a positive feedback regulation system between Treg cells and MCs operating through TGFβ1 and IL-9. Therefore, further research is needed to validate the current results. Ultimately, further experiments could further improve our understanding of the mechanistic interactions between Tregs and MCs.

Acknowledgements

The authors of the present study would like to thank Professor Wu Ke (Wuhan Union Hospital) for critically reading this manuscript.

Funding

The present study was funded by the Natural Science Foundation of Ningbo (grant no. 2015A610223).

Availability of data and materials

All data generated or analyzed during this study are included within the article.

Authors' contributions

HY conceived the study. YZ and HY designed the study. YZ performed the experiments and interpreted the data. SY, JS, KD, QL, YW and WC performed the statistical analysis. All authors have read and approved the final manuscript.

Ethics approval and consent to participate

Human samples were obtained with informed written or oral consent from the donors. The study was approved by the Ethical committee of Ningbo Medical Center Lihuili Hospital (Ningbo, China; approval no. KY2020PJ020).

Competing interests

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.
2. Wang LH, Su L and Wang JT: Correlation between elevated FOXP3 expression and increased lymph node metastasis of gastric cancer. Chin Med J (Engl) 123: 3545-3549, 2010.
3. Yoshii M, Tanaka H, Ohira M, Muguruma K, Iwasaki T, Lee T, Sakurai K, Kubo N, Yashiro M, Sawada T and Hirakawa K: Expression of forkhead box P3 in tumour cells causes immuno-regulatory function of signet ring cell carcinoma of the stomach. Br J Cancer 106: 1668-1674, 2012.
4. Tan Z: Recent advances in the surgical treatment of advanced gastric cancer: A review. Med Sci Monit 25: 3537-3541, 2019.
5. Magalhães H, Fontes-Sousa M and Machado M: Immunotherapy in advanced gastric cancer: An overview of the emerging strategies. Can J Gastroenterol Hepatol 2018: 2732408, 2018.
6. Khazaie K, Blatter NR, Khan MW, Gounari F, Gounaris E, Dennis K, Bonerz A, Tsai FN, Strouch MJ, Cheon E, et al: The significant role of mast cells in cancer. Cancer Metastasis Rev 30: 45-60, 2011.
7. Ribatti D and Crivellato E: Mast cells, angiogenesis, and tumor growth. Biochim Biophys Acta 1822: 2-8, 2012.
8. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, Liu Y, Yuan Y, Yu Z, Xia HM and Feng ZH: SCF-mediates mast cell anti-infiltration and activation correlate the inflammation and immunosuppression in tumor microenvironment. Blood 112: 1269-1270, 2008.
9. Rabinovich GA, Gabriovich D and Sotomayor EM: Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 25: 267-296, 2007.
10. Picones S and Colombo MP: Regulatory T cells in cancer. Blood 108: 804-811, 2006.
11. Fontenot JD, Gavin MA and Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2: 103-111, 2001.
12. Kryczek I, Liu R, Wang G, Wu K, Shu X, Szeliga W, Vatan L, Finlayson E, Huang E, Simczone D, et al: FOXP3 defines regulatory T cells in human tumor and autoimmune disease. Cancer Res 69: 3995-4000, 2009.
13. Ribatti D and Crivellato E: Chapter 4 the controversial role of mast cells in tumor growth. Int Rev Cell Mol Biol 275: 89-131, 2009.
14. Ribatti D, Guidolin D, Maruzzo A, Nico B, Annese T, Benagiano V and Crivellato E: Mast cells and angiogenesis in gastric carcinoma. J Int Exp Pathol 91: 350-356, 2010.
15. Zhao Y, Wu K, Zhi B, Zhu W, Wang G and Wang J: Increased numbers of gastric-infiltrating mast cells and regulatory T cells are associated with tumor stage in gastric adenocarcinoma patients. Oncol Lett 4: 755-758, 2012.
16. De Smedt T, Smith J, Baum P, Fanslow W, Butz E and Maley CC: IL-9 receptor signaling enhances the development of T cell responses induced by dendritic cells in vivo. J Immunol 168: 661-670, 2002.
17. Huang L, Wang M, Yan Y, Gu W, Zhang X, Tan J, Sun H, Ji W and Chen Z: OX40L induces helper T cell differentiation during cell immunity of asthma through PI3K/AKT and P38 MAPK signaling pathway. J Transl Med 16: 74, 2018.
18. Edge SB and Compton CC: The American joint cancer committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TMN. Ann Surg Oncol 17: 1471-1474, 2010.
19. Yuan XL, Chen L, Zhang TT, Ma YH, Zhou YL, Zhao Y, Wang WW, Dong P, Yu L, Zhang YY and Shen LS: Gastric cancer cells induce human CD4+Foxp3+ regulatory T cells through the production of TGF-β1. World J Gastroenterol 17: 2019-2027, 2011.
20. Wang J, Zhang Y, Zeng Y, Ge S, Sun X, Jia M, Wu Y and Wang N: Isoimperatorin reduces the effective dose of dexamethasone in a murine model of asthma by inhibiting mast cell activation. Phytother Res 2020 (Epub ahead of print).
21. Feng LL, Gao JM, Li PP and Wang X: IL-9 contributes to immunosuppression mediated by regulatory T cells and mast cells in patients with gastrointestinal malignancies: Possible involvement of regulatory T cells in disease progression. Cancer 98: 1089-1099, 2003.
22. Shen Z, Zhou S, Wang Y, Li RL, Zhong C, Liang C and Sun Y: Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. Cancer Res 66: 1585-1595, 2010.
23. Mizumami Y, Kono K, Kawaguchi Y, Akaite H, Kamikura M, Sugai H and Fujii H: Localisation pattern of Foxp3+ regulatory T cells is associated with clinical behaviour in gastric cancer. Br J Cancer 98: 148-153, 2008.
24. Bataller A, Montalbano-Brago G, Soltysska KA and Garcia-Manero G: The role of TGFβ in hematopoiesis and myeloid disorders. Leukemia 23: 1076-1089, 2019.
25. Zhu H, Luo H, Shen Z, Hu X, Sun L and Zhu X: Transforming growth factor-β1 in carcinogenesis, progression, and therapy in cervical cancer. Tumour Biol 37: 7075-7083, 2016.
26. Sved V: TGF-β signaling in cancer. J Cell Biochem 117: 1279-1287, 2016.
27. Schwartz M, Zhang Y and Rosenblatt JD: B cell regulation of the anti-tumor response and role in carcinogenesis. J Immunother Cancer 4: 40, 2016.
28. Elieh Ali Komi D and Grauwet K: Role of mast cells in regulation of T cell responses in experimental and clinical settings. Clin Rev Allergy Immunol 54: 432-445, 2018.
29. Matsuizawa S, Sakashita K, Kinoshita T, Ito S, Yamashita T and Koeke K: IL-9 enhances the growth of human mast cell progenitors under stimulation with stem cell factor. J Immunol 170: 5461-5467, 2003.
30. Townsend JM, Fan J, Ronen M, Smith P, Jolin EH and McKenzie NA: IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 13: 573-583, 2000.
31. Schmitt E, Van Brandwijk R, Van Snick J, Siebold B and Räde E: Regulatory murine cd4+ t cells but not a general t cell growth factor. Eur J Immunol 19: 2167-2170, 1989.
32. Lu LF, Lind EF, Gondek DC, Bennett KA, Gleson MW, Pino-Lagos K, Scott ZA, Coyle AJ, Reed JL, Van Snick J, et al: Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature 442: 997-1002, 2006.
33. Beriou G, Bradshaw EM, Lozano E, Costantino CM, Hastings WD, Orban T, Elyaman W, Khoury SJ, Kuchroo VK, Baeccher-Allan C and Hafler DA: TGF-beta induces IL-9 production by human T cells during autoimmunity: A comprehensive review. Clin Rev Allergy Immunol 54: 432-445, 2018.
34. Oberhuber K, Wang WH, Chen Y and O’Shea JJ: Regulatory T cells are required for tissue specific T cell activation during allergic inflammation. J Allergy Clin Immunol 136: 430-441, 2015.
35. Hauber HP, Bergeron C and Hamid Q: IL-9 in allergic inflammation. Int Arch Allergy Immunol 134: 79-87, 2004.
36. Renga G, Moretti S, Otokonouyou Y, Borghi M, Zelante T, Paolicelli G, Costantini C, De Zuan M, Villella VR, Raia V, et al: IL-9 and mast cells are key players in allergy and autoimmunity. Cell Rep 36: 1019-1028, 2020.
37. Kashiwakura J, Yokoi H, Saito H and Okayama Y: T cell proliferation is enhanced by OX40 on human mast cells and OX40 costimulation enhances the development of T cell responses between human T cells and OX40 on human mast cells: Comparison of gene expression by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells. J Immunol 186: 83-91, 2011.
38. Webb GJ, Hirschfeld GM and Lane PJL: OX40, OX40L and coimmunity: A comprehensive review. Clin Rev Allergy Immunol 31: 501-515, 2008.
39. Kashiwakura J, Yokoi H, Saito H and Okayama Y: T cell proliferation is enhanced by OX40 on human mast cells and OX40 costimulation enhances the development of T cell responses between human T cells and OX40 on human mast cells: Comparison of gene expression by direct cross-talk between OX40 ligand on human mast cells and OX40 on human T cells. J Immunol 186: 83-91, 2011.
40. Webb GJ, Hirschfeld GM and Lane PJL: OX40, OX40L and coimmunity: A comprehensive review. Clin Rev Allergy Immunol 31: 501-515, 2008.